Different studies showed the efficacy of venetoclax in the treatment of T-ALL (Peirs et al., 2014; Rahmat et al., 2018; Farhadfar et al., 2021), including early T-cell progenitor (ETP) ALL (Ni Chonghaile et al., 2014) and B-ALL (Hohtari et al., 2022; Zhang et al., 2022), especially those with MLL rearrangements (Benito et al., 2015; Richter-Carpentier et al., 2022). The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.